NYSE$PLX
Protalix Biotherapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Protalix reported fiscal year 2023 financial results, highlighted by regulatory approvals for Elfabrio and advancements in the pipeline.
Protalix BioTherapeutics reported a successful fiscal year 2023, marked by the regulatory approval of Elfabrio in multiple regions and progress in its clinical pipeline, including PRX-115 for severe gout. The company's financial performance showed increased revenues and a shift to net income, positioning it for future growth.
- Elfabrio gained marketing authorizations in the US, EU, UK, Switzerland, and Israel.
- Revenue from selling goods increased by 60% to $40.4 million due to Elfabrio sales.
- The company recorded net income of $8.3 million, a significant turnaround from the previous year's net loss.
- First patient was dosed in Phase I clinical trial of PRX-115 for severe gout.
Headline financials
Revenue & EPS history
Protalix · Revenue · Quarterly
$10.5M
Revenue by segment
Protalix · $3.18M total across 1 segment · Q2 2021
- License & R&D$3.18M—100.0%
Forward guidance
Protalix anticipates continued support for Chiesi's commercial activities and focus on developing a pipeline of innovative assets, with potential for revenue growth and positive impact on patients' lives.
Tailwinds
- Anticipated publication of PRX-115 trial results in Q2 2024
- Potential for revenue growth.
- Focus on developing a rich pipeline of innovative assets.
- Elfabrio launches underway in multiple markets.
- Solid financials
Headwinds
- Risks related to Elfabrio's market acceptance, competition and reimbursement.
- Possible disruption of operations due to armed conflict.
- Risks related to regulatory approval and commercial success of other product candidates.
- Global conditions such as supply chain challenges and inflationary environment may adversely impact the business.
- Dependence on third-party providers of services and supplies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-1.3%
Avg return
Earnings day
-1.7%
Avg return
5 days after
-5.6%
Avg return
30 days after
44%
28 / 64 earnings
Positive
+15.7%
Q2 2023
Best reaction
-36.4%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +0.0% | +9.5% | |
| Q4 2025 | +1.8% | -23.7% | -16.8% | |
| Q3 2025 | -10.9% | -12.1% | -16.4% | |
| Q1 2025 | +0.0% | +2.4% | -10.8% | |
| Q4 2024 | +9.4% | +11.2% | +16.1% | |
| Q3 2024 | +12.9% | +31.5% | +45.2% | |
| Q2 2024 | -8.7% | -7.7% | +1.0% | |
| Q1 2024 | -8.8% | -9.6% | -10.4% | |
| Q4 2023 | -12.5% | -14.5% | -22.4% | |
| Q3 2023 | -18.9% | -27.6% | -14.1% | |
| Q2 2023 | +15.7% | +15.7% | +13.9% | |
| Q1 2023 | +3.8% | -7.3% | -29.8% | |
| Q4 2022 | +6.6% | +12.6% | +11.0% | |
| Q3 2022 | +0.9% | +1.9% | +10.5% | |
| Q2 2022 | -0.4% | -2.4% | -11.4% | |
| Q1 2022 | +0.9% | +7.5% | +1.9% | |
| Q4 2021 | +0.0% | +40.0% | +10.5% | |
| Q3 2021 | -3.5% | -14.0% | -21.9% | |
| Q2 2021 | +2.2% | +0.0% | -0.7% | |
| Q1 2021 | +0.7% | -1.0% | -24.4% | |
| Q4 2020 | -5.1% | -4.5% | -24.7% | |
| Q3 2020 | -7.9% | -9.3% | +2.0% | |
| Q2 2020 | +2.2% | +3.3% | -6.1% | |
| Q1 2020 | +2.7% | +7.5% | +12.3% | |
| Q4 2019 | -3.0% | -5.1% | +3.8% | |
| Q3 2019 | -5.2% | -8.7% | +34.8% | |
| Q2 2019 | -36.4% | -29.7% | -40.5% | |
| Q1 2019 | -2.7% | -6.8% | -15.9% | |
| Q4 2018 | +1.8% | -6.1% | -12.2% | |
| Q3 2018 | -5.2% | -14.3% | -12.2% | |
| Q2 2018 | -2.0% | +0.0% | -6.0% | |
| Q1 2018 | +2.2% | +12.5% | +15.0% | |
| Q4 2017 | -1.4% | +1.5% | -33.8% | |
| Q3 2017 | -6.6% | -1.4% | -15.1% | |
| Q2 2017 | -4.6% | -12.3% | -4.6% | |
| Q1 2017 | -6.0% | -13.0% | -5.4% | |
| Q4 2016 | -4.7% | -14.1% | -18.0% | |
| Q3 2016 | +12.1% | +34.1% | -26.8% | |
| Q2 2016 | -1.5% | -1.6% | -4.7% | |
| Q1 2016 | -0.6% | — | — | |
| Q4 2015 | +4.7% | — | — | |
| Q3 2015 | -3.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -1.3% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -2.5% | — | — | |
| Q3 2013 | +0.2% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +4.0% | — | — | |
| Q3 2012 | +1.3% | — | — | |
| Q2 2012 | +1.4% | — | — | |
| Q1 2012 | +2.8% | — | — | |
| Q4 2011 | -1.5% | — | — | |
| Q3 2011 | +1.3% | — | — | |
| Q2 2011 | -9.7% | — | — | |
| Q1 2011 | -0.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q2 2010 | +0.1% | — | — | |
| Q1 2010 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro